Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients

By Safra Tamar   Ron Ilan   Boaz Mona   Brenner Joseph   Grisaru Dan   Inbar Moshe   Hayat Henry   Menczer Joseph   Golan Abraham   Levy Tally  

Acta Oncologica, Vol. 45, Iss. 4, 2006-06 ,pp. : 463-468

Informa Healthcare

Access to resources Recommend Favorite

Third-line gemcitabine monotherapy for platinum-resistant advanced urothelial cancer

By Soga Norihito   Kise Hideaki   Arima Kiminobu   Sugimura Yoshiki  

International Journal of Clinical Oncology, Vol. 15, Iss. 4, 2010-08 ,pp. : 376-381

Springer Publishing Company

Access to resources Recommend Favorite

Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy

By Leitao M.M.   Hummer A.   Dizon D.S.   Aghajanian C.   Hensley M.   Sabbatini P.   Venkatraman E.   Spriggs D.R.  

Gynecologic Oncology, Vol. 91, Iss. 1, 2003-10 ,pp. : 123-129

Elsevier

Access to resources Recommend Favorite

Phase II Study of Gemcitabine and Docetaxel in Recurrent Platinum Resistant Ovarian Cancer

By Garcia Agustin A.   Yessaian Anne   Pham Huyen   Facio Grace   Muderspach Laila   Roman Lynda  

Cancer Investigation, Vol. 30, Iss. 4, 2012-04 ,pp. : 295-299

Informa Healthcare

Access to resources Recommend Favorite

A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer

By Westermann A.M.   Grosen E.A.   Katschinski D.M.   Jager D.   Rietbroek R.   Schink J.C.   Tiggelaar C.L.   Jager E.   Zum Vorde sive Vording P.   Neuman A.   Knuth A.   Van Dijk J.D.P.   Wiedemann G.J.   Robins H.I.  

European Journal of Cancer, Vol. 37, Iss. 9, 2001-06 ,pp. : 1111-1117

Elsevier

Access to resources Recommend Favorite